Biomarkers in Obesity: Serum Myeloperoxidase and Traditional Cardiac Risk Parameters

Borato, Danielle Cristyane Kalva; Parabocz, Gisele Chibinski; Ribas, Josilaine Tonin; Netto, Harli Pasquini; Erdmann, Friederike; Wiecheteck, L. D.; Manente, Francine Alessandra; Mello, Lucas Rosolen de Almeida; Belló, Caroline; Santos, Fábio André dos; Borba, Luciana Maria; Vellosa, José Carlos Rebuglio

doi:10.1055/s-0035-1565093

Cited by 17 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of another HDL associated, pro-atherogenic enzyme: myeloperoxidase was also investigated. In line with some previous studies [ 27 , 28 ] we found significantly higher myeloperoxidase level in obese subjects compared to lean controls. Previous data shows that MPO, PON1, and HDL may bind to each other, forming a ternary complex, wherein PON1 partially inhibits MPO activity and MPO inactivates PON1 influencing endogenous oxidative stress and lipid peroxidation during inflammation [ 29 ].…”

Section: Discussionsupporting

confidence: 93%

Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients

et al. 2018

View full text Add to dashboard Cite

BackgroundObestatin is a ghrelin-associated peptide, derived from preproghrelin. Although many of its effects are unclear, accumulating evidence supports positive actions on both metabolism and cardiovascular function. To date, level of obestatin and its correlations to the lipid subfractions in non-diabetic obese (NDO) patients have not been investigated.MethodsFifty NDO patients (BMI: 41.96 ± 8.6 kg/m2) and thirty-two normal-weight, age- and gender-matched healthy controls (BMI: 24.16 ± 3.3 kg/m2) were enrolled into our study. Obestatin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions, intermediate density lipoprotein (IDL) and very low-density lipoprotein (VLDL) levels and mean LDL size were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint).ResultsSerum level of obestatin was significantly lower in NDO patients compared to controls (3.01 ± 0.5 vs. 3.29 ± 0.6 μg/ml, p < 0.05). We found significant negative correlations between the level of obestatin and BMI (r = − 0.33; p < 0.001), level of serum glucose (r = − 0.27, p < 0.05), HbA1c (r = − 0.38; p < 0.001) and insulin (r = − 0.34; p < 0.05). Significant positive correlation was found between obestatin level and the levels of ApoA1 (r = 0.25; p < 0.05), large HDL subfraction ratio and level (r = 0.23; p < 0.05 and r = 0.24; p < 0.05), IDL (r = 0.25 p < 0.05) and mean LDL size (r = 0.25; p < 0.05). Serum VLDL ratio and level negatively correlated with obestatin (r = − 0.32; p < 0.01 and r = − 0.21; p = 0.05). In multiple regression analysis obestatin was predicted only by VLDL level.ConclusionsBased on our data, measurement of obestatin level in obesity may contribute to understand the interplay between gastrointestinal hormone secretion and metabolic alterations in obesity.

show abstract

Section: Discussionsupporting

confidence: 93%

Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This condition contribute to macrophage and neutrophil activation and consequent release of MPO, which was demonstrated to be increased in obese subjects in the study of Borato et al . 32 . Moreover, Shukla et al .…”

Section: Discussionmentioning

confidence: 99%

Myeloperoxidase is not a good biomarker for preeclampsia prediction

Rocha-Penha

Bettiol

Barbieri

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Myeloperoxidase is a proinflammatory enzyme found to be increased in patients with established preeclampsia but never investigated before the disease onset. Here we examined myeloperoxidase concentration and activity in plasma and urine samples from pregnant women who remained normotensive throughout pregnancy and those who developed preeclampsia in order to assess its potential to predict this disorder. Our sample consisted of 30 cases who developed preeclampsia (14 severe and 16 mild) and 57 controls who remained healthy throughout pregnancy, derived from the Brazilian Ribeirão Preto and São Luís prenatal cohort (BRISA). Myeloperoxidase concentration were assessed using a commercial ELISA kit and enzymatic activity through tetramethylbenzidine oxidation. No statistical differences were found in myeloperoxidase levels nor activity between plasma or urine samples from controls, severe and mild cases. Myeloperoxidase did not seem to have a potential application for preeclampsia prediction.

show abstract

“…A study of MPO as an early biomarker of inflammation and obesity in prepubertal obese children indicated an MPO level of about 22 µg/L, as compared to normal weight children with an MPO level of about 14 µg/L. Thus, these studies support the hypothesis that serum myeloperoxidase is a suitable and potential biomarker for assessing various cardiovascular risks among obese patients [ 156 ].…”

Section: Role Of Myeloperoxidase In Different Diseasesmentioning

confidence: 53%

Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives

2018

View full text Add to dashboard Cite

Myeloperoxidase (MPO) belongs to the family of heme-containing peroxidases, produced mostly from polymorphonuclear neutrophils. The active enzyme (150 kDa) is the product of the MPO gene located on long arm of chromosome 17. The primary gene product undergoes several modifications, such as the removal of introns and signal peptides, and leads to the formation of enzymatically inactive glycosylated apoproMPO which complexes with chaperons, producing inactive proMPO by the insertion of a heme moiety. The active enzyme is a homodimer of heavy and light chain protomers. This enzyme is released into the extracellular fluid after oxidative stress and different inflammatory responses. Myeloperoxidase is the only type of peroxidase that uses H2O2 to oxidize several halides and pseudohalides to form different hypohalous acids. So, the antibacterial activities of MPO involve the production of reactive oxygen and reactive nitrogen species. Controlled MPO release at the site of infection is of prime importance for its efficient activities. Any uncontrolled degranulation exaggerates the inflammation and can also lead to tissue damage even in absence of inflammation. Several types of tissue injuries and the pathogenesis of several other major chronic diseases such as rheumatoid arthritis, cardiovascular diseases, liver diseases, diabetes, and cancer have been reported to be linked with MPO-derived oxidants. Thus, the enhanced level of MPO activity is one of the best diagnostic tools of inflammatory and oxidative stress biomarkers among these commonly-occurring diseases.

show abstract

Biomarkers in Obesity: Serum Myeloperoxidase and Traditional Cardiac Risk Parameters

Cited by 17 publications

References 39 publications

Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients

Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients

Myeloperoxidase is not a good biomarker for preeclampsia prediction

Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives

Contact Info

Product

Resources

About